[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ocd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ocd":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,42,75,102,132,175,217,239,270,313,335,366,390,411,430,461,497,520],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100309842","locating-biomarkers-in-ocd-through-behavioral-tasks-100309842",false,"NCT03313622","Locating Biomarkers in OCD Through Behavioral Tasks","Locating Biomarkers of Medically Intractable Obsessive Compulsive Disorder (OCD) Through the Use of Behavioral Tasks","Inclusion Criteria:\n\n* Diagnosis of OCD\n* Non-pregnant if female\n* Minimum score of 16 on Y-BOCS\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Those not meeting inclusion criteria listed above\n* Lifetime diagnosis of psychotic disorders such as schizophrenia\n* Alcohol or substance abuse\u002Fdependence within 6 months, excluding nicotine\n* Deemed at high risk of suicidal behavior or impulsivity\n* Pregnant or plans to become pregnant in the next 24 months","ALL","18 Years","65 Years",{"count":20,"type":21},20,"ESTIMATED","OBSERVATIONAL","Subjects that have a diagnosis of OCD will participate in a clinical interview and cognitive tasks, during which they will be exposed to their individual OC stressors or will be asked to make decisions related to information value and quantity while measuring neural activity and filming facial reactions. This will assist investigators to look for biomarkers of that change. This study offers a unique opportunity to develop biomarkers for key domains of OCD, and other neuropsychiatric disorders, that are grounded in brain neurocircuitry at the individual-patient level.\n\nSubjects will participate in a clinical interview (Day 1), and then tasks+EEG (Day 2). Day 1 will be 4 hours or less, and Day 2 will be 2.5 hours or less.",[25,26],"OCD","Obsessive-Compulsive Disorder",[25,28],"Obsessive Compulsive Disorder","NOT_YET_RECRUITING","2026-06-26",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":21},"2027-03",{"date":37,"type":21},"2028-03",{"name":39,"class":40},"Baylor College of Medicine","OTHER",3,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":41},"100644110","digital-coach-to-support-exposure-therapy-homework-for-anxious-youth-100644110","NCT07666672","Digital Coach to Support Exposure Therapy Homework for Anxious Youth","Randomized Controlled Trial of the BraveBot Intervention as an Adjunctive Treatment for Young People With Anxiety and Related Disorders Receiving Outpatient, Exposure-Based Cognitive Behavioral Therapy","INCLUSION CRITERIA (youth participants):\n\n1. Has a clinical or subclinical anxiety or related disorder (e.g., panic disorder, social anxiety disorder, obsessive-compulsive disorder) for which exposure-based CBT is indicated.\n2. Between the ages of 12 and 22 years at the time of enrollment.\n3. Is either (a) currently receiving exposure-based CBT (or CBT in which exposure-based content is expected to be a core component) at a participating MGB outpatient program, or (b) on the waitlist for a participating program and expected to initiate exposure-based CBT in the near future.\n4. Sufficient ability to communicate in English (study materials, measures, and the BraveBot interface are currently English-only). For minors, at least one parent\u002Fguardian must be sufficiently proficient in English to understand the consent information.\n5. The youth and\u002For caregiver has access to a device that can receive SMS text reminders and open secure web links to complete exposure homework and brief post-exposure surveys.\n\nEXCLUSION CRITERIA (present at enrollment):\n\n1. Symptoms of suicidal or homicidal ideation, psychosis, or a non-anxiety-related primary mental health concern (i.e., where treatment for a disorder other than anxiety is indicated prior to exposure treatment, or independent exposure homework is not clinically appropriate as determined by the treating clinician). Examples include: current substance use or dependence requiring specialized or higher-level care that must be addressed before or instead of anxiety-focused exposure-based CBT; and current eating disorder severe enough to require intensive\u002Fspecialized treatment such that exposure-based CBT for anxiety\u002FOCD is not the appropriate primary focus.\n2. Youth is unable to complete homework independently.\n3. Any other condition or circumstance for which treatment for another primary psychiatric condition is clearly indicated prior to anxiety-focused exposure-based CBT, or for which out-of-session exposure homework is considered unsafe or inappropriate.\n\nThe investigators will also recruit up to 10 clinicians at participating programs who may use the BraveBot system with their patients (who have enrolled in the study independently) and complete brief baseline and end-of-study surveys.","12 Years","22 Years",{"count":52,"type":21},50,"INTERVENTIONAL",[55],"NA","This study is testing a digital tool called BraveBot for young people who are receiving cognitive behavioral therapy (CBT) for anxiety, OCD, or related problems. BraveBot is a computer program, not a person. It talks with youth through their phone or computer while they do \"face-your-fears\"-style exposure therapy homework that their therapist has assigned. Sometimes an exposure is done with BraveBot's real-time coaching, and sometimes on their own; after each exposure, youth answer a few short questions about how it went.\n\nRather than dividing participants into separate groups, the study randomizes each individual exposure homework assignment. Every time a young person opens an eligible exposure, the system makes a 1:1 random assignment deciding whether that exposure is completed with BraveBot's support or independently (self-guided).\n\nThe main goal is to learn whether using BraveBot helps youth understand their exposure assignments better, put in more effort, stick with exposures when they are hard, feel more capable, and find exposures more helpful in \"fighting back\" against anxiety. The study also examines whether BraveBot increases the likelihood that assigned exposures are completed, and explores effects on anxiety symptoms and how safe, easy to use, and useful BraveBot feels for youth, their therapists, and parents.\n\nBraveBot does not replace the therapist, diagnose, or design exposures; it only supports the homework the clinician has assigned, and is used under clinician oversight. A built-in safety system can detect possible risk-related language, pause the session, show crisis resources (such as 988), and notify the treating clinician. The study is conducted within routine outpatient psychology clinics at Mass General Brigham. Up to 40 youth ages 12-22 will take part.",[58,25],"Anxiety Disorders",[60,61,62,63,64,65],"anxiety","exposure therapy","pediatric","large language model","conversational AI","randomized controlled trial","2026-06-18",{"date":68,"type":33},"2026-06-24",{"date":70,"type":21},"2026-07-15",{"date":72,"type":21},"2027-07-15",{"name":74,"class":40},"Massachusetts General Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":53,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100466885","how-hormones-and-exposure-and-response-prevention-exrp-affect-the-brain-of-people-with-ocd-100466885","NCT05359562","How Hormones and Exposure and Response Prevention (EX\u002FRP) Affect the Brain of People With OCD","Harnessing Hormonal Variation to Probe Neural Mechanisms and Optimize CBT Outcomes for OCD","Inclusion Criteria:\n\n1. Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Diagnosis of OCD;\n2. Male and female subjects aged between 18- 45;\n3. Women must be menstruating and regularly cycling\n4. Ability to tolerate a treatment-free period;\n5. No psychotropic medication in the past 12 weeks\n6. At entry, at least moderate severity OCD\n7. Willingness and ability to give written informed consent after full explanation of study procedures.\n\nExclusion Criteria:\n\n1. Use of birth control (oral contraception or IUD) that affects the menstrual cycle, or menopause.\n2. Pregnancy. Women of childbearing potential will be required to sign a statement indicating their intention to avoid pregnancy during the study.\n3. Neurologic or medical condition that would prevent safe participation in the full study protocol.\n4. Any contradiction to magnetic resonance imaging (e.g., metallic implants or devices).\n5. Comorbid psychiatric conditions that significantly elevate the risks associated with study participation or confound results.\n6. Patients with prominent suicidal ideation or with a recent suicide attempt.\n7. Current psychotherapy","45 Years",{"count":84,"type":21},120,[55],"Studies show that hormones affect the brain's fear extinction network, which is relevant for therapy involving exposure and response prevention (EX\u002FRP), a first-line treatment for obsessive compulsive disorder (OCD). This study will examine the effect of delivering EX\u002FRP to women during different phases in their menstrual cycle to determine the effects of hormones on the fear extinction network and on their OCD symptoms.",[25],[25,89,90],"Exposure and Ritual Prevention","Extinction Learning","RECRUITING","2026-06-17",{"date":94,"type":33},"2026-06-22",{"date":96,"type":33},"2022-06-15",{"date":98,"type":21},"2028-06-30",{"name":100,"class":40},"University of Pennsylvania",2,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":110,"targetDuration":4,"studyType":53,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100639223","effect-of-emotion-focused-acceptance-and-commitment-therapy-on-obsessive-compulsive-disorder-symptom-severity-100639223","NCT07622654","Effect of Emotion-Focused Acceptance and Commitment Therapy on Obsessive-Compulsive Disorder Symptom Severity","The Effect of Emotion-Focused Acceptance and Commitment Therapy on Obsessive-Compulsive Disorder Symptom Severity: A Randomized Controlled Trial","ACT-OCD","Inclusion Criteria:\n\n* Diagnosis of Obsessive-Compulsive Disorder according to DSM-5 criteria\n* Age between 18-65 years\n* Minimum literacy level\n* Willingness to participate and providing informed consent\n\nExclusion Criteria:\n\n* Age over 65 years\n* Diagnosis of alcohol or substance use disorder\n* Comorbid psychotic disorder or intellectual disability\n* Any change in psychiatric treatment (medication or psychotherapy) in the last 3 months\n* Comorbid psychiatric disorder that would impair group therapy compliance\n* History of cognitive impairment due to dementia, organic brain syndrome or other neurological\u002Forganic pathology",{"count":111,"type":21},36,[55],"This study aims to investigate the effect of Emotion-Focused Acceptance and Commitment Therapy (ACT) group psychotherapy on obsessive-compulsive disorder (OCD) symptom severity. Participants with OCD will be randomly assigned to either an ACT-based group psychotherapy arm or a supportive group psychotherapy arm. Each arm consists of 10 to 12 weekly sessions of 2 hours. Symptom severity, psychological flexibility, emotional awareness, functioning and quality of life will be assessed before and after the intervention.",[25,115],"Obsessive - Compulsive Disorder",[117,118,26,119,25,120,121],"ACT","Acceptance and Commitment Therapy","Group Psychotherapy","Emotion-Focused Therapy","Psychological Flexibility","2026-05-30",{"date":124,"type":33},"2026-06-03",{"date":126,"type":33},"2025-10-01",{"date":128,"type":21},"2026-06-01",{"name":130,"class":40},"Mehmet Emrah Karadere",1,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":140,"maxAge":17,"enrollmentInfo":141,"targetDuration":4,"studyType":53,"phases":143,"briefSummary":144,"conditions":145,"keywords":160,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":131},"100587910","implementing-team-based-treatment-for-pediatric-anxiety-in-community-mental-health-settings-100587910","NCT06934525","Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings","Testing Delivery of Modalities in Community Health Settings: Developing Pathways to Health Equity","IMPACT-RI","Inclusion Criteria:\n\n* Age 5-18 inclusive\n* Primary or co-primary DSM-V diagnosis of anxiety or OCD\n* Symptom duration of at least 3 months\n* Outpatient care needed\n* Presence of a stable parent, or guardian, who can participate in treatment\n\nExclusion Criteria:\n\n* Other primary or co-primary psychiatric disorder which requires initiation of other active current treatment\n* Acute suicidality\n* Concurrent psychotherapy\n* Chronic medical illness that would preclude their active participation in treatment\n* Treatment with psychotropic medication that is not stable","5 Years",{"count":142,"type":21},501,[55],"The purpose of this study is to test how the delivery of Cognitive Behavioral Therapy (CBT) for pediatric anxiety and OCD via different methods might increase its availability and effectiveness. CBT involves teaching the patient skills to enable them to gradually come into contact with feared situations. This process of gradually approaching feared situations is called exposure. Although CBT with exposure has the best evidence for treating anxiety disorders, not all children have equal access or respond the same way to CBT. As part of this study, patients will receive weekly CBT treatment sessions involving a combination of weekly visits with an exposure coach and one visit a month with a licensed provider (e.g., psychologist, social worker). This treatment will be delivered using one of three methods: 1) in-person (face-to-face sessions, occurring in the office and the home\u002Fcommunity), or 2) telehealth (entirely remote sessions via web-based video conference), or 3) flexible (individualized mix of in-person and\u002For telehealth sessions). Eligible participants will be randomly assigned to one of these three methods. Results of this study will help determine which treatment method works best for whom.\n\nTreatment as described above will occur as part of care at partnering community care sites in Rhode Island. Providers from the following partnering community care sites will make up patient treatment teams: Blackstone Valley Community Health Care, Family Services of Rhode Island, Gateway Healthcare, Newport Mental Health, and Thrive Behavioral Health.\n\nThe research study is being conducted by the Pediatric Anxiety Research Center at Brown University Health. The research team will conduct the study assessments that patients will be asked to participate in as study participants. Patients will be asked to complete assessments prior to starting treatment, at two time points during treatment, at the end of treatment, and at two timepoints 3 and 6 months following the end of treatment. Participants will be compensated for their time completing research assessments.",[146,147,148,149,25,150,151,152,153,154,155,156,157,158,159],"Obsessive Compulsive Disorder (OCD)","Pediatric Anxiety Disorders","Anxiety Disorder","Anxiety","Phobia","Agoraphobia","Generalized Anxiety","Generalized Anxiety Disorder","Selective Mutism","Separation Anxiety","Social Anxiety","Social Anxiety Disorder","Panic Disorder","Pediatric Disorders",[61,161,162,163,164,165],"cognitive behavioral therapy","anxiety treatment","exposure and response prevention therapy","ERP","pediatric anxiety treatment","2026-05-13",{"date":168,"type":33},"2026-05-14",{"date":170,"type":33},"2025-11-01",{"date":172,"type":21},"2029-08-01",{"name":174,"class":40},"Bradley Hospital",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":182,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":185,"conditions":186,"keywords":196,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":101},"100564051","computer-game-qualitative-and-megeeg-assessment-of-serotonergic-psychedelics-100564051","NCT06624137","Computer Game, Qualitative, and MEG\u002FEEG Assessment of Serotonergic Psychedelics","Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects","Inclusion Criteria:\n\n* Participation in approved clinical protocol at Yale University involving potential administration of serotonergic psychedelics\n* Absence of pre-existing psychotic symptoms\n\nExclusion Criteria:\n\n* Current intoxication based on self-report\n* Any neurological, medical or developmental problem that is known to impair cognition significantly based on self-report\n* History of seizures based on self-report\n* Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia (specific to those who will participate in MRI)",true,{"count":184,"type":21},200,"This is an observational study which does NOT directly administer a psychedelic substance but rather recruits participants who are already participating in another clinical trial in which they may receive a serotonergic psychedelic. The goal of this observational study is to learn how the brain's information processing changes during and following administration of serotonergic psychedelics (psilocybin, N,N-Dimethyltryptamine\u002FDMT, Lystergic Acid Diethylamide\u002FLSD, etc.) for people with and without mental illness receiving serotonergic psychedelics through any clinical trial at Yale University. The main questions it aims to answer are:\n\n1. Do serotonergic psychedelics cause the brain to rely on new information more than previously learned information while under the influence? What about 1 day, 5-14 days, and 4-6 weeks after use?\n2. Do serotonergic psychedelics cause long-lasting side-effects in how people perceive (see, hear, feel, etc.) the world and how easily people change their beliefs?\n3. How does the brain's electrical activity change after using serotonergic psychedelics? How does the balance between excitation and inhibition change while under their effect?\n4. Can changes in how the brain uses information predict who will benefit from a psychedelic and who will have side effects from psychedelics?\n\nResearchers will compare with people given placebos to see what changes in brain processing are unique to serotonergic psychedelics.\n\nParticipants will have the opportunity to do some combination of the following:\n\n1. Online computer assessments consisting of games and questionnaires that probe how participants think.\n2. Magnetoencephalography (MEG) or electroencephalography (EEG) with eyes closed and with repeated clicks, images, or sensations delivered.\n3. A magnetic resonance imaging (MRI) scan.\n4. Semi-structured qualitative interviews about their experience after taking a serotonergic psychedelic recorded via Zoom.",[25,187,188,189,190,191,192,193,194,146,195],"Major Depressive Disorder (MDD)","Alcohol Use Disorder (AUD)","Healthy Volunteer","Migraine","PTSD","PTSD - Post Traumatic Stress Disorder","Addiction","Tobacco Use Disorder","Opioid Use Disorder",[197,198,199,200,201,202,203,204,205,206,207],"Psilocybin","DMT","N,N-dimethyltryptamine","Ayahuasca","Lysergic acid diethylamide","LSD","5-MeO-DMT","O-methyl-bufotenin","eeg","meg","5-Methoxy-N,N-Dimethyltryptamine","2026-04-27",{"date":210,"type":33},"2026-05-01",{"date":212,"type":33},"2024-12-12",{"date":214,"type":21},"2028-05",{"name":216,"class":40},"Yale University",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":140,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":131},"100592754","retrospective-analyses-of-the-greenbrook-database-evaluating-mental-health-treatments-100592754","NCT06997549","Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments","Inclusion Criteria:\n\n* Male or female reported in database and not an invalid entry\n* Age reported and not an invalid entry\n* Treatment date in 2011 or later.\n\nExclusion Criteria:\n\n• Incomplete information on treatment parameters","100 Years",{"count":225,"type":21},12000,"The study involves multiple retrospective analyses to understand the utilization of mental health treatments provided at Greenbrook and their effectiveness",[228,25,229],"Depression","Anxiety Depression","2026-04-06",{"date":232,"type":33},"2026-04-09",{"date":234,"type":33},"2025-05-15",{"date":236,"type":21},"2035-12",{"name":238,"class":40},"Neuronetics",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":182,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":53,"phases":247,"briefSummary":249,"conditions":250,"keywords":256,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":131},"100550081","phase-1-open-label-psilocybin-study-in-transdiagnostic-population-100550081","NCT06442423","Open-Label Psilocybin Study in Transdiagnostic Population","Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and\u002For Addiction Symptoms: An Open-label Proof-of-concept Study","Inclusion Criteria:\n\n1. At least one psychiatric symptom causing functional impairment over the past 30 days as established by a trained rater on the DIAMOND (at least \"mild\" impairment) and\u002For the WHODAS-2.0 12-item (a raw score of \\>16) - assessment instruments indexing health and disability.\n2. English fluency - able to understand the process of consent and the risk and benefits associated with the study, and able to provide written (signed and dated) informed consent form.\n3. Agree to set up safe transportation after leaving the site following the dosing session. Acceptable arrangements include: arranging for a friend\u002Ffamily member to drive them home, pick them up and escort them home; if the participant is unable to arrange for a friend\u002Ffamily member to escort them home, the study staff will arrange private transportation and follow up with the participant to ensure that they arrived at their destination.\n4. Must be able to identify a physician\u002Ftreater that can be contacted to further assure that it is safe for the subject to participate and agree to sign a medical release for the investigators to communicate directly with this outside provider to confirm treatment and medical history via phone and\u002For email.\n5. Ability to orally ingest pills for psilocybin dosing visit.\n6. Must provide an adult contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the PI and\u002For study personnel in the event of an emergency, and who can provide transportation for study visits if necessary and independently comment on any changes in the participant's mood or behavior after the administration of psilocybin. Be medically stable (no medical issues based on physical exam, labs and medical evaluation) as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an ECG, and routine blood and urinalysis laboratory tests (see section 6.3.4 for labs). Must also demonstrate decisional capacity based on clinical assessment ensuring the participant can understand, appreciate, and reason through the study's purpose, procedures, and associated risks, as well as tolerate the potential effects of the study medication.\n7. Be psychologically stable: Concurrent psychotherapy is allowed if the type and frequency of the therapy has been stable for at least one month prior to screening and is expected to remain stable during participation in the study (up to 4-weeks post-dosing).\n8. If participant is of childbearing potential, must agree to use adequate birth control and not attempt to become pregnant during study up to 4 weeks post dosing session (see Section 6.3.3).\n\nIf participant is of childbearing potential, must have a negative urine pregnancy test at study entry and prior to the dosing session. Participants who are FOCBP must not plan to become pregnant or donate eggs, starting at least 1 month before receiving the trial intervention and for at least 1 week after the final follow-up visit.\n\nA FOCBP is defined as a female who is considered fertile following menarche and until becoming postmenopausal, unless permanently sterile (see below).\n\nFemales in the following categories are not considered FOCBP:\n\n* Premenarchal.\n* Premenopausal with 1 of the following:\n\n  1. Documented hysterectomy or bilateral salpingectomy\u002Ftubal occlusion\u002Foophorectomy.\n  2. Postmenopausal.\n* A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.\n* Females receiving hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use 1 of the nonhormonal, highly effective contraception methods if they wish to continue their HRT during the trial.\n\nExclusion Criteria:\n\nPsychiatric Exclusion Criteria:\n\n1. Personal history of a primary psychotic disorder (e.g., schizophrenia, delusional disorder, schizoaffective disorder) or Bipolar I disorder, or at least one first-degree relative with a diagnosis of primary psychotic disorder (e.g., schizophrenia, delusional disorder, schizoaffective disorder) or Bipolar I disorder.\n2. Active suicidal intent or suicidal or non-suicidal self-injurious behaviors, as defined by a \"yes\" response to question 4 on C-SSRS within the past 6 months at screening or prior to dosing (Active Suicidal Ideation with Some Intent to Act, with or without Specific Plan).\n3. Use of a classic psychedelic (i.e., LSD, psilocybin, DMT, mescaline) within the 3 months prior to enrollment (not including microdosing).\n4. Use of ketamine within the past month at Screening.\n5. History of regular and frequent use of a classic psychedelic (more than 10 times per year) in a structured, intentional setting over the past 10 years. Structured use refers to participation in organized retreats, ceremonies, or church services. Microdosing is not included.\n6. History of Other Hallucinogen Use Disorder.\n7. History of intolerance to drugs known significantly to alter perception (i.e., psilocybin, LSD, salvinorium A, mescaline).\n8. Patients taking 5-hydroxytryptophan or St. John's Wort\n9. A positive breathalyzer test\n10. A positive urine toxicology screening, which detects the standard panel of five drugs (marijuana, cocaine, opioids\u002Fopiates, amphetamines, and phencyclidine (PCP)), as well as benzodiazepines, 3,4-methylenedioxymethamphetamine (MDMA). If a participant tests positive for any of these substances, the PI may request a retest during the screening phase. The exceptions to the exclusion are prescribed opioid pain medication and benzodiazepines, or over-the-counter non-narcotic pain medication. If a participant is prescribed benzodiazepines, the participant will be asked to refrain from taking on the day of the psilocybin dosing session. Additionally, participants will not be excluded from the study based on the use of cannabis. However, they will be instructed to refrain from use of cannabis on the day before, day of, and day following the drug administration session. Participants whose primary clinical presenting issue is substance use-related will not be excluded based on a positive test at screening but will be expected to adhere to the dosing day drug test produces (outlined in section 6.3.6).\n11. Changes to psychotropic medication and\u002For dosages within the past 3 months.\n12. Current or recent (within 2 weeks of enrollment) prescription of MAOI, Lithium, and\u002For methadone use.\n13. Has a psychiatric condition that precludes the establishment of therapeutic rapport as evidenced by long-term patterns of unstable relationships, a history of significant stress- related paranoia, or identity disturbances.\n14. Use of any other investigational drugs within 30 days prior to Screening.\n15. Allergy to gelatin.\n\nGeneral Medical\u002FLaboratory Exclusion Criteria:\n\n1. Hypertension at screening is defined as: systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg, on the lowest of three measurements.\n2. History of cardiovascular disease, including but not limited to clinically significant coronary artery disease, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, angina pectoris, coronary artery bypass graft or artificial heart valve, stroke, transient ischemic attack, or any clinically significant arrhythmia.\n3. Any clinically significant abnormal electrocardiogram (ECG) finding, such as findings suggestive of ischemia or infarct, complete bundle branch block, atrial fibrillation or other symptomatic arrhythmias, or predominantly non-sinus rhythm, at Screening.\n4. Resting QT interval with Fridericia's correction (QTcF) ≥ 450 msec (male) or ≥ 470 msec\n\n   a. (female) at Screening, or inability to determine QTcF interval.\n5. Presence of risk factors for torsades de pointes, including: long QT syndrome, uncontrolled hypokalemia or hypomagnesemia, history of cardiac failure, history of clinically significant\u002Fsymptomatic bradycardia, family history of idiopathic sudden death or congenital long QT syndrome, or concomitant use of a torsadogenic medication.\n6. Moderate-to-severe hepatic impairment, defined as a Child-Pugh score ≥ 5, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2 x the upper limit of normal (ULN), or bilirubin \\> 1.5 x ULN, unless this is attributable to Gilbert's syndrome\n7. Use of vasoconstrictive medications (i.e. sumatriptan, pseudoephedrine, midodrine) within 5 half-lives of test days and use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in the past 2 weeks.\n8. Moderate-to-severe renal impairment, defined as an estimated glomerular filtration rate of \\\u003C 50 mL\u002Fmin\u002F1.73 m2 at Screening\n9. Uncontrolled diabetes with an HbA1c \\> 8\n10. Significant uncontrolled hypothyroidism (thyroid stimulating hormone \\[TSH\\] \\\u003C 0.8 x lower limit of normal) with the exception of stably treated hypothyroidism and uncontrolled hyperthyroidism (thyroid stimulating hormone \\[TSH\\] \\\u003C 0.8 x \\> 1.5 x upper Any other condition, disorder or finding which in the opinion of the investigator would adversely impact participant safety or the ability of the participant to complete the study, including compliance with all study requirements and procedures.",{"count":52,"type":21},[248],"PHASE1","The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing. The investigators will recruit individuals with mood, anxiety, trauma, addictive, or related symptomatology, and who have functional impairment associated with these symptoms. A DSM-5 diagnosis is not required (nor is it an exclusion). The investigators will allow for comorbidity and only exclude based on psychological and physiological safety considerations. Critically, this approach will allow us to assess the tolerability of our interventions in individuals who would typically be excluded from efficacy studies due to various comorbid DSM-5 conditions.\n\nThe investigators will employ an open-label study where participants will be given one dose of oral psilocybin 25mg. The investigators will also have follow-up visits at 1, 4, and 6 weeks and an optional long-term follow-up at 3, 6, and 12 months.",[251,252,149,253,191,254,255,25],"Transdiagnostic","Depression - Major Depressive Disorder","PTSD Symptoms","Substance Use","Substance Use Disorder (SUD)",[257,60,258,259,191,25,260,261],"depression","substance use","addiction","psilocybin","psychedelic","2026-03-10",{"date":264,"type":33},"2026-03-11",{"date":266,"type":33},"2024-10-17",{"date":268,"type":21},"2027-12",{"name":216,"class":40},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":53,"phases":280,"briefSummary":281,"conditions":282,"keywords":295,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":131},"100493968","neurostimulation-versus-therapy-for-problems-with-emotions-100493968","NCT05712057","Neurostimulation Versus Therapy for Problems With Emotions","Neurostimulation Enhanced Cognitive Restructuring for Transdiagnostic Emotional Dysregulation: A Component Analysis","Inclusion Criteria:\n\n* age 18 to 55\n* elevated overall score on Difficulties with Emotion Regulation Scale (DERS total score \\>=90)\n* has been in the same type of psychotherapy (including none) for the last 4 weeks\u002F1mo (\\*except for current CBT) and is willing to stay on the same regimen throughout the study.\n* low self-reported use of cognitive restructuring (ERQ restructuring subscale average score \\\u003C 4.7)\n* meets criteria for at least one mood (including Bipolar II w\u002Fo current hypomania), anxiety, stressor, OCD, Impulse Control, ADHD, or eating DSM-5 disorder (except exclusionary diagnoses such as severe anorexia). Note: Both current or partial remission of the disorder will be ok for inclusion into the study.\n* verbal agreement to maintain dose of prescribed psychotropic medication (if any) constant throughout the study, provided they are stable on it for the past 4 weeks (except exclusion medication and except if there is a medical emergency requiring changes in medication).\n* Naïve to rTMS\n\nExclusion Criteria:\n\n* current hypomania (Note: Bipolar II w\u002Fo current hypomanic episode is ok for inclusion)\n* meets diagnostic criteria for current or history of psychotic disorder, or psychotic features,\n* meets diagnostic criteria for Bipolar I disorder\n* meets diagnostic criteria on SCID5 for current alcohol or substance use disorder (moderate and high severity) or meets past history of severe alcohol use disorder\n* unable to read, blind, or deaf, or unwilling to give consent\n* non-English speaker,\n* verbal IQ \\\u003C 90 on the North American Adult Reading Test (NART).\n* current uncontrolled anorexia or other condition requiring hospitalization\n* high risk for suicide defined as either having attempted suicide in past 6 months or reporting current suicidal ideation that includes a method, plan, or intent to die\n* current serious medical illness, including current severe migraine headaches\n* started\u002Fchanged psychotropic medications in the prior 4 weeks, or plans to change medication during the study\n* history of seizure except those therapeutically induced by ECT (childhood febrile seizures are acceptable and these subjects may be included in the study), history of epilepsy in self or first degree relatives, stroke, brain surgery, head injury, cranial metal implants, known structural brain lesions that are contraindications for TMS, devices that may be affected by TMS (pacemaker, medication pump, cochlear implant, implanted brain stimulator), have left elbow\u002Fhand\u002Fwrist tendonitis\n* conditions associated with increased intracranial pressure, space occupying brain lesion (considered significant and unsafe for TMS by the study MD), transient ischemic attack, cerebral aneurysm, dementia, Parkinson's or Huntington's disease, multiple sclerosis\n* Wellbutrin \\>300mg per day or on daily stimulant\u002FADHD medications above the recommended FDA daily recommendations\n* use of investigational drug or devices within 4 weeks of screening\n* cochlear implants\n* Pregnancy\n* metal in body that would exclude them from the MRI scan; severe claustrophobia\n* is a prisoner or in police custody at time of screening, or has pending court case jeopardizing the participation in the study\n* has had TMS in their lifetime\n* has had CBT in the past 4 weeks or plans to start therapy during the study\n* weighs over 300 pounds (could not fit in MRI scanner)","55 Years",{"count":279,"type":21},240,[55],"The primary goal of this clinical trial is to evaluate the unique neural and behavioral effects of a one-session training combining emotion regulation skills training, with excitatory repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC). The secondary aim is to identify key changes in the emotion regulation neural network following the combined intervention versus each of the components alone. The third aim is to explore personalized biomarkers for response to emotion regulation training.\n\nParticipants will undergo brain imaging while engaging in an emotional regulation task. Participants will be randomly assigned to learn one of two emotion regulation skills. Participants will be reminded of recent stressors and will undergo different types of neurostimulation, targeted using fMRI (functional MRI) results. Participants who may practice their emotion regulation skills during neurostimulation in a one-time session. Following this training, participants will undergo another fMRI and an exit interview to assess for immediate neural and behavioral changes. Measures of emotion regulation will be assessed at a one week and a one month follow up visit.",[283,284,285,58,25,286,287,288,289,290,291,292,26,293,294],"Emotion Regulation","Mood Disorders","Stress Disorder","Impulse Control Disorder","Eating Disorders","Emotional Dysfunction","Emotional Instability","Emotional Distress","Emotional Maladjustment","Emotional Impulsivity","Emotion Dysregulation","Borderline Personality Disorder",[293,296,297,298,299,300,301,302,303],"Distress Intolerance","Neuromodulation","Neurostimulation","TMS","cognitive restructuring","regulation skills","neuroimaging","Emotion regulation","2026-03-02",{"date":306,"type":33},"2026-03-04",{"date":308,"type":33},"2023-05-15",{"date":310,"type":21},"2027-12-01",{"name":312,"class":40},"Duke University",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":53,"phases":322,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":131},"100437936","accelerated-tms-for-depression-and-ocd-100437936","NCT04982757","Accelerated TMS for Depression and OCD","Inclusion Criteria:\n\n* Diagnosis of major depressive disorder OR obsessive-compulsive disorder (DSM-V criteria)\n* Hamilton Depression Rating Scale score greater than or equal to 18 OR Yale-Brown Obsessive-Compulsive Scale score greater than or equal to 16\n* Failed at least 1 prior trial of standard first-line treatment for depression or OCD per the modified Antidepressant Treatment History form and APA Practice Guidelines (e.g. serotonin reuptake inhibitor \\[SRI\\] or cognitive behavioral therapy with exposure and response prevention) OR had refused these treatments for individual reasons (e.g., cannot tolerate side effects, cannot tolerate exposure therapy, etc.).\n* Off antidepressants OR on a stable dose of antidepressants for greater than or equal to four weeks with plans to remain on this stable dose during the study Note: Medications that are known to increase cortical excitability (e.g., buprorion, maprotiline, tricyclic antidepressants, classical antipsychotics) or to have an inhibitory effect on brain excitability (e.g., anticonvulsants, benzodiazepines, and atypical antipsychotics), or any other medications with relative hazard for use in TMS will be allowed upon review of medications and\u002For motor threshold determination by TMS specialist.\n* Capacity to consent\n\nExclusion Criteria:\n\n* Imminent risk of suicide (based on the CSSRS)\n* Presence of primary psychiatric diagnoses other than OCD, MDD and\u002For co-morbid GAD (ex. PTSD, MDD with psychotic features, primary psychotic illness, Bipolar I or II)\n* Evidence of cognitive impairment (MMSE score falling 1 SD below mean score for his\u002Fher age and education)\n* Evidence of psychotic symptoms on diagnostic interview (interfering with capacity to consent)\n* Have met criteria for any significant substance use disorder within the past 6 months\n* Recent onset (within 8 weeks of screening) of psychotherapy\n* Prior completion of this accelerated TMS treatment protocol during the current depressive episode\n* Participated in any clinical trial with an investigational drug or device within the past 6 weeks prior to screening\n* Evidence or history of significant neurological disorder including moderate-severe head trauma, stroke, Parkinson's disease or other movement disorder (except benign essential tremor), epilepsy\n* History of seizures (except juvenile febrile seizures) or any condition\u002Fconcurrent medication that could notably lower seizure threshold\n* Presence of foreign metal bodies\u002Fimplanted intracranial devices (MRI contraindication)\n* Current pregnancy or planning to conceive during the study\n* Abnormal bloodwork for electrolytes, thyroid or liver function","75 Years",{"count":321,"type":21},500,[55],"Repetitive transcranial magnetic stimulation (rTMS) is a FDA-approved treatment for depression and Obsessive Compulsive Disorder (OCD). The goal of the study is to learn how to optimize the treatment to improve symptoms of depression and OCD. This research project will test a new accelerated 5-day accelerated rTMS protocol for treating symptoms of depression and OCD.\n\nA second goal of this study is to identify biomarkers of depression and OCD in the brain using functional magnetic resonance imaging (fMRI). This approach will predict who will benefit from TMS, determine the optimal treatment target, and improve treatment outcomes. Subjects will receive a clinical assessment of symptoms and an fMRI brain scan before and after each treatment course to measure the effect of treatment on symptom severity and on fMRI measures of functional connectivity.\n\nParticipants will be randomized to receive rTMS targeting either the lateral prefrontal cortex (LPFC) or the dorsomedial prefrontal cortex (DMPFC). Participants will complete a 5-day course of rTMS delivered hourly for 10 hours per day. Participants who show a partial response to treatment but not a full response will then receive a second 5-day course. Treatment non-responders will be crossed over to receive rTMS targeting the opposite brain area.\n\nThe primary hypothesis is that accelerated rTMS treatment will yield rapid improvement in symptoms for patients with depression and OCD in just 5 days, and that response rates can be further improved by adding a second 5-day treatment course.",[228,25],[299],"2026-02-24",{"date":328,"type":33},"2026-02-27",{"date":330,"type":33},"2021-12-07",{"date":332,"type":21},"2027-08",{"name":334,"class":40},"Weill Medical College of Cornell University",{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":342,"maxAge":18,"enrollmentInfo":343,"targetDuration":4,"studyType":53,"phases":344,"briefSummary":345,"conditions":346,"keywords":349,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":41},"100519962","objective-characterizatoion-of-repetitive-behaviors-100519962","NCT06050369","Objective Characterizatoion of Repetitive Behaviors","Actimetric and Electrophysiological Analyses of Repetitive Behaviors (Tics and Compulsions)","Inclusion Criteria:\n\n* To be more of 15 years old or less than 65 years old\n* To suffer from OCD and\u002For GTS (depressive, anxious and attention deficit hyperactivity disorder (ADHD) comorbidities are accepted)\n* To be registered to the french social security (or something equivalent)\n* To give written consent to participate to the research\n* To have contraception for women participants (or to not have any sexual activity)\n\nExclusion Criteria:\n\n* Patients with any other psychiatric disorders than those mentioned in the inclusion criteria\n* Patients with any other neurological disorder than GTS\n* Patients who are not able to take decisions for themselves\n* Pregnant women\n* Patients not allowed to get MRI due to contraindication\n* Patients not speaking french","15 Years",{"count":52,"type":21},[55],"Introduction:\n\nRepetitive behaviors (RB) constitute a broad range of symptoms across different psychiatric\u002Fneurologic disorders. The most famous are stereotypies (found in autism), compulsions (found in obsessive-compulsive-disorder, OCD) and tics (found in Gilles de la Tourette syndrome, GTS). For some patients, it is sometime difficult to distinguish the nature of the repetitive behaviors presented, however this distinction is crucial in order to chose the appropriate treatment.\n\nAim:\n\nIn our study, the investigators will try to define electrophysiological and accelerometric marker of both OCD and tics to allow objective distinction between both tics and compulsions.\n\nMethod:\n\nSubjects: Both OCD and GTS patients will be recruited, 25 patients in each group.\n\nProtocol: our study protocol will involve two step: a step in laboratory, another step at patient home.\n\n* first step: both patients group will be recorded through a high density EEG and a portative EEG while doing a task of symptom provocation. Then they will get an anatomical MRI for source recontruction. Finally, the patients will have to mimic their symptom while wearing an accelerometer (a smartwatch).\n* second step: both patient groups will be recorded at home through a portative EEG while tagging their symptom through a smartwatch (also used for accelerometry). After the recording, the patients will keep the smartwatch for 2 weeks, still tagging their sympoms (compulsions or tics).",[25,347,348],"Tic Disorders","Gilles de la Tourette Syndrome",[350,351,352,353,354,355],"Electrophysiology","Electroencephalogram","EEG","Accelerometer","Biomarker","Symptom provocation","2026-02-10",{"date":358,"type":33},"2026-02-12",{"date":360,"type":33},"2023-12-28",{"date":362,"type":21},"2027-12-27",{"name":364,"class":365},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":182,"sex":16,"minAge":17,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":377,"conditions":378,"keywords":379,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":131},"100504078","cerebral-and-cognitive-markers-of-treatment-resistance-in-obsessive-compulsive-disorder-100504078","NCT05843604","Cerebral and Cognitive Markers of Treatment Resistance in Obsessive Compulsive Disorder","Cerebral and Cognitive Markers of Treatment Resistance in Obsessive-compulsive Disorder: Towards Personalization of Patient Care","3TOC","Inclusion Criteria:\n\n* Obsessive compulsive disorder diagnosed according to Diagnostic and Statistical Manual 5 criteria (patients will be included regardless of the severity and resistance of their pathology and their levels of executive functions)\n* Understand and accept the constraints of the study\n* Be a beneficiary or affiliated to a Health Insurance scheme\n\nExclusion Criteria:\n\n* Present one of the diagnoses according to the criteria of the DSM 5: schizophrenic disorders, substance abuse or dependence to a substance according to the criteria of the M.I.N.I. version 5.0 (Sheehan et al., 1998)\n* Generalized anxiety disorder, social anxiety, nicotine dependence and history of a major depressive episode are not exclusion criteria according to the M.I.N.I. version 5.0 (Sheehan et al., 1998)\n* Have a serious intercurrent pathology\n* Being a pregnant woman\n* Being a woman of childbearing age without effective contraception.\n* Being hospitalized under duress or on an outpatient basis in a care program\n* Being under judicial protection (reinforced curatorship, guardianship)","70 Years",{"count":376,"type":21},100,"This study aims to define individual profiles of treatment resistants in order to find indicators and predictors of the therapeutic response.",[25],[380],"functional MRI","2026-01-12",{"date":383,"type":33},"2026-01-13",{"date":385,"type":33},"2023-07-03",{"date":387,"type":21},"2027-09",{"name":389,"class":40},"Centre Hospitalier Henri Laborit",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":277,"enrollmentInfo":397,"targetDuration":4,"studyType":53,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":131},"100483867","paired-tvns-with-erp-in-ocd-100483867","NCT05580614","Paired tVNS With ERP in OCD","Pairing tVNS and Exposure and Response Prevention to Improve Symptoms of OCD","Inclusion Criteria:\n\n* Adults between the ages of 18 and 55\n* Meet DSM-5 criteria for OCD, based on a structured clinical interview and who have a YBOCS score of 15 or higher, indicating at least moderate OCD severity\n* Participants must be willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Participants with major neurological conditions, autism spectrum disorder, psychosis, major uncorrected sensory deficit, and severe medical disease that may be associated with neurological effects.\n* People with an active eating disorder that requires treatment, but we will not exclude people who are in remission.\n* Current illicit or prescription drug abuse\n* Participants who are receiving pharmacotherapy for their OCD or for other psychiatric disorders will not be excluded\n* No medication changes will be allowed during the study, and participants must be on stable doses of medications for at least 6 weeks prior to entering the study. Prior ERP treatment (at least 12 months removed) is acceptable",{"count":398,"type":21},56,[55],"In the proposed investigation, the investigator will develop pilot data for the use of tVNS (transcutaneous vagal nerve stimulation) to enhance efficacy of exposure and response prevention therapy (ERP) to improve treatment success in patients with OCD. This data will include tolerability information from therapists and patients with OCD, effect sizes on real world clinical outcomes for the combinatory treatment, and mechanistic data on brain changes associated with treatment.",[25],"2025-10-24",{"date":404,"type":33},"2025-10-27",{"date":406,"type":33},"2022-06-27",{"date":408,"type":21},"2026-08-31",{"name":410,"class":40},"University of Florida",{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":182,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":53,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":428,"locationsCount":131},"100515634","neuromodulation-for-a-novel-ocd-biomarker-and-treatment-100515634","NCT05994053","Neuromodulation for a Novel OCD Biomarker and Treatment","Inclusion Criteria:\n\n(1) a primary DSM-5 diagnosis of OCD, (2) a score of 16 or greater on the YBOCS (3) at least 18 years of age; and (4) willingness and ability to provide informed consent and comply with the requirements of the study protocol.\n\nExclusion Criteria:\n\n(1) a lifetime history of bipolar or psychotic disorders; (2) history of Tourette syndrome; (3) psychosurgery; (4) substance abuse or dependence (other than nicotine) in the past 3 months; (5) organic brain syndrome, mental retardation or other potentially interfering cognitive dysfunction; (6) severe depression (MADRS score of 30 or greater); (7) suicidal risk as determined by moderate or greater score on the Columbia Suicide Severity Rating Scale (C-SSRS); (8) pregnancy or lactation; (9) changes to pharmacotherapy for OCD or the initiation of cognitive-behavior therapy within the last 3 months; and (10) specific to the tACS and EEG procedures no metal implants in head, any implanted electronic devices, any skin sensitivity, color blindness or impaired vision despite correction, claustrophobia, and any history of epilepsy or neurological disorder.",{"count":418,"type":21},90,[55],"Although multiple treatments for OCD exist, slow symptom decrease, high remission, and significant side effects for some OCD patients limit their efficacy. More research into the precise neural mechanisms and linked cognitive functions in OCD is also necessary. To address both concerns, this study by Dr. Reinhart and his team will test a new, non-invasive, and well-tolerated neuromodulation method for reducing OCD symptoms, based on reward-related rhythms of the orbitofrontal cortex (OFC; a brain region responsible for reward, decision making and other crucial functions that is affected by OCD). This proposal is based on highly encouraging preliminary data in both subsyndromal and treatment-resistant populations that shows rapid reductions in OCD behaviors that last at least 1-3 months. Using high-definition transcranial alternating current stimulation (HD-tACS) guided by EEG brain wave recordings, the study will test whether repetitive modulation of relevant rhythm activity in the OFC can lead to rapid (within five days) and sustainable (up to three months) OCD symptom reduction. This research aims to increase knowledge of OCD and development of effective treatment with minimal side effects.",[25],"2025-09-15",{"date":424,"type":33},"2025-09-17",{"date":426,"type":33},"2024-07-01",{"date":408,"type":21},{"name":429,"class":40},"Boston University Charles River Campus",{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":182,"sex":16,"minAge":438,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":53,"phases":442,"briefSummary":444,"conditions":445,"keywords":446,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":131},"100571425","early-phase-1-light-therapy-for-obsessive-compulsive-disorder-ocd-100571425","NCT06720090","Light Therapy for Obsessive-compulsive Disorder (OCD)","Light Therapy for Obsessive-compulsive Disorder: A Circadian Medicine Approach","KLTO","Inclusion Criteria:\n\n1. Primary DSM-5 OCD diagnosis\n2. Bedtime 0100 or later\n3. Age 18-35\n4. English speaking\n\nExclusion Criteria:\n\n1. Subjects must not be currently participating in another research study that would influence their participation in our study.\n2. Diagnostic status\n3. Treatment status\n4. Night shift work or travel more than 1 time zone outside of Central Standard Time (CST) in the past month\n5. Pregnancy status\n6. Medication status\n7. Regular nicotine or marijuana use","17 Years","35 Years",{"count":441,"type":21},40,[443],"EARLY_PHASE1","The goal of this clinical trial is to test whether light therapy is effective for reducing symptoms in young adults with OCD and late bedtimes (1am or later). The main question\\[s\\] it aims to answer are:\n\nDoes light therapy reduce OCD symptoms? Does light therapy advance the circadian clock? If there is a comparison group: Researchers will compare a higher dose of light therapy to a lower dose to see if dose amount affects symptom reduction.\n\nParticipants will asked to:\n\n1. Wear light therapy glasses for 1 hour each morning and complete a daily light therapy log for 5 weeks\n2. Track their sleep every day with a wearable monitor and an electronic sleep diary for 5 weeks\n3. Complete a 1-time assessment of sensitivity to light exposure\n4. Complete self-report measures of OCD 4 times\u002Fday at baseline (2 weeks), mid-treatment (1 week), and end of treatment (1 week)",[25],[447,448,449,450,451],"ocd","sleep","light therapy","circadian","behavioral treatment","2025-07-14",{"date":454,"type":33},"2025-07-15",{"date":456,"type":33},"2024-12-16",{"date":458,"type":21},"2029-03",{"name":460,"class":40},"Washington University School of Medicine",{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":182,"sex":16,"minAge":468,"maxAge":469,"enrollmentInfo":470,"targetDuration":140,"studyType":22,"phases":4,"briefSummary":472,"conditions":473,"keywords":478,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":493,"leadSponsor":495,"locationsCount":131},"100591286","behavioural-development-long-term-outcomes-and-opportunities-to-optimize-youth-mental-health-trajectories-100591286","NCT06978452","Behavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health Trajectories","BLOOM","Inclusion Criteria:\n\nYouth between 9 to 25 years of age at inclusion, who are able to read and understand either French or English, with at least one parent or legal guardian available to consent for those under 18 years of age.\n\nSpecific eligibility criteria:\n\nHelp-seeking group: At least one help-seeking contact made with a primary care clinical service provider or agency (e.g, paediatric\u002Ffamily physician clinic, CLSC or Aire Ouverte) for a mental health concern (i.e., clinical needs).\n\nNon help-seeking group:\n\nAt least one of the birth parents or siblings have received psychiatric care for a diagnosis of DMDs (i.e., family needs) OR Being in contact with community agencies that provide youth-centred social services for food, housing, social discrimination (e.g., racialized youth, LGBTQ2SIA+) (i.e., social needs) OR Having a diagnosed chronic physical illness that is expected to require treatment for \\>12 months (e.g., diabetes, asthma to name a few) (i.e., physical health needs)\n\nExclusion Criteria:\n\n* Due to the requirements of assessment procedures, youth who cannot communicate verbally due to known neurological conditions or intellectual disabilities will not be included. Youth who are already diagnosed with one of the DMDs by a physician and currently prescribed a treatment targeting the diagnosed condition (pharmacological or psychotherapeutic interventions), will not be eligible for inclusion.\n\nImportantly, no one will be excluded based on sex, gender, health insurance status, ethnicity, income status, ability to travel or living arrangements. If a participant initially approached through the referral pathways for non help-seeking individuals turns out to have had at least one help-seeking contact for a mental health concern (i.e., clinical needs), the participant will still be included but classified as part of the help-seeking group. We anticipate non help-seeking referrals to satisfy more than one criteria. Their occurrence and distribution will be recorded in detail as part of our assessment procedure.","9 Years","25 Years",{"count":471,"type":21},560,"Behavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health (BLOOM) is a project that aims to overcome age and diagnostic boundaries to generate person-specific longitudinal profiles of mental health in youth aged 9 to 25. The overarching objective is to lay the informational foundation to accurately predict both clinical outcomes and opportunities to optimize health trajectories. This project will recruit youth in need without any mental health diagnosis and follow them annually for 5 years. The present study includes assessment of antecedents, opportunities and outcomes that will establish eligibility for preventive interventions",[252,474,475,476,477,255,25],"Bipolar","Psychosis","Eating Disorder NOS","ADHD",[479,480,481,482,483,484,485,486,487,488],"antecedents","mental health prevention","resilience","access to care","help-seeking","youth in needs","biomarker","speech","language","cognition","2025-05-11",{"date":491,"type":33},"2025-05-18",{"date":426,"type":33},{"date":494,"type":21},"2029-07-01",{"name":496,"class":40},"Douglas Mental Health University Institute",{"id":498,"slug":499,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":53,"phases":506,"briefSummary":507,"conditions":508,"keywords":509,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":131},"100572296","multi-session-personalized-cognitive-bias-modification-for-thought-action-fusion-100572296","NCT06731426","Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion","Effects of Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion Among Adults with Obsessive-Compulsive Symptoms: a Randomized Controlled Trial","Inclusion Criteria:\n\n* A score of 18 or higher on the Dimensional Obsessive-Compulsive Scale (DOCS)\n* Aged 18 or higher\n* Access to a mobile device (i.e., smartphone)\n\nExclusion Criteria:\n\n* Self-reported visual impairment that cannot be adjusted and will prevent them from clearly recognizing words and pictures on mobile screen\n* Self-reported history of a bipolar disorder or psychotic disorder on a Diagnostic History Scale (DHS)\n* Inability to adequately understand the study procedure as determined by the responses to comprehension questions provided at the time of the consent",{"count":505,"type":21},84,[55],"Thought-Action-Fusion (TAF) is a cognitive bias that posits (1) having unwanted thoughts is morally equivalent to acting upon the thoughts (TAF-Moral; e.g., \"Thinking about harming a child is as immoral as actually harming a child\") and (2) having unwanted thoughts will increase the likelihood of the thoughts happening in real life (TAF-Likelihood; e.g., \"My mother will get into a car accident, because I thought about it\"). Given its central role in the development and maintenance of OCD, TAF has emerged as a potential treatment target for obsessive-compulsive disorder (OCD). Previous research has demonstrated that TAF is indeed a malleable construct. This study aims to examine the effects of a multi-session, personalized cognitive bias modification (CBM) for thought-action-fusion (TAF) on improving obsessive-compulsive (OC) symptoms in a college sample.",[25],[510,511],"Cognitive Bias Modification","Personalization","2024-12-09",{"date":212,"type":33},{"date":515,"type":33},"2024-04-18",{"date":517,"type":21},"2026-05-31",{"name":519,"class":40},"Han Joo Lee",{"id":521,"slug":522,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":528,"conditions":529,"keywords":530,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":131},"100506974","discovering-factors-in-the-clinical-study-journey-of-patients-with-ocd-100506974","NCT05881356","Discovering Factors in the Clinical Study Journey of Patients With OCD","Understanding the Patient Perspective: An Observational Study on Experiences of OCD Clinical Trial Patients","Inclusion Criteria:\n\n* Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.\n* Participant has a diagnosis of OCD.\n* Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.\n\nExclusion Criteria:\n\n* Pregnant or lactating woman\n* Enrolled in another research study\n* Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial",{"count":321,"type":21},"This research aims to collect comprehensive data on the clinical trial experience of OCD patients. Its goal is to identify the factors that limit patients' ability to join or complete a trial successfully. Clinical trial participation often favors specific demographic groups, and limited research exists on the impact of trial attributes on participation. Therefore, this study aims to analyze data from various demographic groups and identify any recurring trends that could provide valuable insights for future OCD patients.",[25,26],[25,26],"2023-05-19",{"date":533,"type":33},"2023-05-31",{"date":535,"type":21},"2024-06",{"date":537,"type":21},"2026-06",{"name":539,"class":540},"Power Life Sciences Inc.","INDUSTRY"]